The latest update is out from Verrica Pharmaceuticals ( (VRCA) ).

On Wednesday, dermatology drug developer Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released preliminary results from Part 2 of its Phase 2 trial of VP-315 for basal cell carcinoma. The Phase 2 trial ...

Fintel reports that on December 18, 2025, Brookline Capital upgraded their outlook for Verrica Pharmaceuticals (NasdaqCM:VRCA ...

Shares of Verrica Pharmaceuticals Inc. (VRCA) have been struggling lately and have lost 15.3% over the past week. However, a hammer chart pattern was formed in its last trading session, which could ...

As of August 2, 2023, the average one-year price target for Verrica Pharmaceuticals is 12.58. The forecasts range from a low of 10.10 to a high of $15.75. The average price target represents an ...

Total Revenue: $14.3 million for Q3 2025, compared to negative $1.8 million in Q3 2024. Torii Milestone and Collaboration Revenue: $10.7 million in Q3 2025. Net YCANTH Revenue: $3.6 million in Q3 2025 ...

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) ...

The FDA approved Verrica Pharmaceuticals Inc's VRCA Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients two years of age and older. Molluscum ...